Observational studyNeuroradiology2017
Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study.
Observational study in Neuroradiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Is the Swallow Tail Sign a Useful Imaging Biomarker in Clinical Neurology? A Systematic Review.Movement disorders clinical practice · 2025Pooled it
- Loss of the "swallow tail sign" on susceptibility-weighted imaging in the diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis.Journal of neurology · 2024Pooled it
- The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis.European journal of nuclear medicine and molecular imaging · 2020Pooled it
- Deep learning-based susceptibility map-weighted imaging analysis of dorsal nigral hyperintensity as a surrogate for dopamine transporter positron emission tomography in patients with idiopathic rapid eye movement sleep behavior disorder.Frontiers in neurology · 2026Article
- High resolution multi-parametric probabilistic in vivo atlas of dorsolateral nigral hyperintensity via 7 T MRI.Scientific data · 2025Article
- Review
- Article
- Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions.Frontiers in neurology · 2024Review
- Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging.Insights into imaging · 2023Review
- Differentiating dementia with Lewy bodies from Alzheimer's disease and Parkinson's disease dementia: an update on imaging modalities.Journal of neurology · 2022Review
- MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Article
- Fast 3 T nigral hyperintensity magnetic resonance imaging in Parkinson's disease.Scientific reports · 2021Article
- Proportional Changes in Cognitive Subdomains During Normal Brain Aging.Frontiers in aging neuroscience · 2021Article
- Neuropsychological tests are useful for predicting comorbidities of idiopathic normal pressure hydrocephalus.Acta neurologica Scandinavica · 2020Article
- Neuroimaging in Lewy body dementia.Journal of neurology · 2019Review
- Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.Yonago acta medica · 2018Review
- Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease.European radiology · 2018Article
- MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?AJNR. American journal of neuroradiology · 2017Article
- Is Hippocampal Volumetry Really All That Matters?AJNR. American journal of neuroradiology · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe characteristics of dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and amnestic mild cognitive impairment (a-MCI) overlap but require different treatments; therefore, it is important to differentiate these pathologies. Assessment of dopamine uptake in the striatum using dopamine transporter (DaT) single-photon emission computed tomography (SPECT) is the gold standard for diagnosing DLB; however, this modality is expensive, time consuming and involves radiation exposure. Degeneration of the substantia nigra nigrosome-1, which occurs in DLB, but not in AD/a-MCI, can be identified by 3T susceptibility-weighted imaging (SWI). Therefore, the aim of this retrospective observational study was to compare SWI with DaT-SPECT for differentiation of DLB from AD/a-MCI.
methodsSWI data were acquired for patients with clinically diagnosed DLB (n = 29), AD (n = 18), a-MCI (n = 13) and healthy controls (n = 26). Images were analysed for nigrosome-1 degeneration. Diagnostic accuracy was evaluated for DLB, AD and a-MCI compared with striatal dopamine uptake using DaT-SPECT.
resultsSWI achieved 90% diagnostic accuracy (93% sensitivity, 87% specificity) for the detection of nigrosome-1 degeneration in DLB and not in AD/a-MCI as compared with 88.3% accuracy (93% sensitivity, 84% specificity) using DaT-SPECT.
conclusionsSWI nigrosome-1 evaluation was useful in differentiating DLB from AD/a-MCI, with high accuracy. This less invasive and less expensive method is a potential alternative to DaT-SPECT for the diagnosis of DLB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.